HALO's 48% Q2 Jump Looks Real-But Can the Beat-and-Raise Hold Through 2026?

The beat-and-raise reset 2026 expectations

Halozyme did more than beat the second-quarter bar. It raised the standard for the rest of 2026. The company delivered Q2 revenue of $481 million against roughly $410 million expected, along with adjusted EPS of $2.28 versus $1.82. Management then lifted its full-year outlook, now targeting $1.835 billion to $1.910 billion in 2026 revenue. The key point is not just the quarter itself, but the fact that the stronger results were tied to actual sales and royalty growth.

Why the market reacted

The quality of the quarter matters. Halozyme reported record second-quarter results, including $307.7 million in royalty revenue and $129.6 million in product sales. That points to genuine demand for products built on the company's technology, rather than a result driven mainly by financial engineering or accounting maneuvering.

The stock response reflected that confidence. Halozyme said shares were up in pre-market trading after the better-than-expected results and improved 2026 outlook, and the stock has gained 27.5% year to date versus 4.4% for the industry. The bigger implication is that investors began repricing the full-year story, not just one quarter.

Enhanze adoption is visible in marketed partner drugs

What Enhanze is doing for partners

Enhanze is Halozyme's delivery platform for developing subcutaneous formulations of certain already-marketed drugs. By helping convert some intravenous therapies into under-the-skin alternatives, the technology can make treatment more convenient for patients and gives partners another way to extend the commercial life of existing assets.

The commercial footprint is already real

That is why the marketed footprint matters. Halozyme already has partnered drugs using Enhanze that are in use commercially, including the subcutaneous formulation of Darzalex, Vyvgart Hytrulo, and Phesgo. When those products are selling, Halozyme is earning royalties from assets that already have commercial validation.

The royalty line makes that tangible. Halozyme reported royalty revenue of $307.7 million in the second quarter, up 50% from a year earlier. Royalty growth was driven mainly by subcutaneous Darzalex and Vyvgart Hytrulo, which supports the view that this quarter reflected real partner demand rather than a one-off accounting effect.

The raised full-year outlook matters for the same reason. Halozyme is now looking for $1.835 billion to $1.910 billion in 2026 revenue, a higher bar that matches the royalty momentum seen in the second quarter.

The main question is durability, not whether the story is real

The bear case is not that Halozyme lacks commercial traction. The more reasonable concern is whether growth will stay steady or come in waves. A business built around a small set of marketed partner products can be somewhat lumpy, with quarter-to-quarter results affected by timing, mix, or launch acceleration.

One way to judge whether that risk is fading is to watch the partner pipeline. Management said it had signed five new ENHANZE and Hypercon collaboration agreements year to date through July, ahead of its full-year goal of three. If those partnerships eventually produce marketed products, Halozyme would have a broader set of royalty drivers than it does today.

What has to happen for HALO to justify higher expectations

The quarter showed the business is real. The next few quarters need to show that the higher bar can hold.

The near-term scoreboard

What matters now is whether Halozyme can build on the raised 2026 guidance frame and the higher EPS outlook without the growth looking like a one-off burst. After a quarter that improved the company's near-term outlook, another headline beat alone will not be enough. Investors need evidence that the higher expectations can be maintained.

That means watching the current royalty drivers for steady commercial momentum. If those partner drugs continue to sell well, Halozyme should continue to benefit through royalties. If momentum cools, the market may start to question how durable the beat-and-raise really was.

From partnerships to revenue conversion

New deal activity can support the long-term story, but it is not the same as current revenue. Five new collaboration agreements is a positive sign, but the next test is conversion: turning those partnerships into visible commercial output. That is where the narrative becomes a sturdier valuation case.

For now, the setup looks operationally sound. The main risk is not a lack of demand or weak product-market fit. It is whether Halozyme can keep this growth pattern consistent enough to match the higher bar management just set.